Content area
Abstract
Background
Cancer becomes lethal as it spreads from the primary site to the rest of the body. Circulating tumor cells (CTCs) are biomarkers of disease progression and have been associated with decreased overall survival. Blood filtration is a novel concept for removing CTCs from circulation to improve patient prognosis.
Methods
This study utilizes liquid biopsy to assess the efficacy of ExThera Medical’s Seraph® 100 Microbind® Affinity Blood Filter on the blood of patients with pancreatic ductal adenocarcinoma (PDAC) using the third generation high-definition single cell assay workflow. Blood samples from treatment-naïve PDAC patients were collected and analyzed to characterize the CTCs and other rare cells present before and after filtration.
Results
Examination of 6 paired portal vein blood (PoVB) samples demonstrated a statistically significant decrease in total rare cells, total cytokeratin (CK)+ cells, and CTCs across all patients due to filtration. Furthermore, analysis of 2 paired peripheral blood (PB) samples showed a decrease in total rare cells, total CK+ cells, and specific phenotypes of rare cells after filtration.
Discussion
These preliminary results demonstrate initial proof of concept that this filtration device can remove CTCs from circulation and may therefore be useful as a therapy or adjunct in PDAC patient care.
Details
1 University of Southern California, Convergent Science Institute for Cancer, Michelson Center, Los Angeles, USA (GRID:grid.42505.36) (ISNI:0000 0001 2156 6853)
2 University of Southern California, Convergent Science Institute for Cancer, Michelson Center, Los Angeles, USA (GRID:grid.42505.36) (ISNI:0000 0001 2156 6853); University of Southern California, Institute of Urology, Catherine & Joseph Aresty Department of Urology, Keck School of Medicine, Los Angeles, USA (GRID:grid.42505.36) (ISNI:0000 0001 2156 6853); University of Southern California, Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, USA (GRID:grid.42505.36) (ISNI:0000 0001 2156 6853)
3 Cedars Sinai Medical Center, Pancreatic and Biliary Diseases Program, Los Angeles, USA (GRID:grid.50956.3f) (ISNI:0000 0001 2152 9905)
4 Cedars Sinai Medical Center, Departments of Medicine and Pathology, Los Angeles, USA (GRID:grid.50956.3f) (ISNI:0000 0001 2152 9905); VA Greater Los Angeles Medical Center, Department of Pathology, Los Angeles, USA (GRID:grid.414855.9) (ISNI:0000 0004 0445 0551); Clark Atlanta University, Center for Cancer Research and Development, Atlanta, USA (GRID:grid.254275.3) (ISNI:0000 0001 2224 3669)
5 University of Southern California, Convergent Science Institute for Cancer, Michelson Center, Los Angeles, USA (GRID:grid.42505.36) (ISNI:0000 0001 2156 6853); University of Southern California, Institute of Urology, Catherine & Joseph Aresty Department of Urology, Keck School of Medicine, Los Angeles, USA (GRID:grid.42505.36) (ISNI:0000 0001 2156 6853); University of Southern California, Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, USA (GRID:grid.42505.36) (ISNI:0000 0001 2156 6853); University of Southern California, Department of Biomedical Engineering, Viterbi School of Engineering, Los Angeles, USA (GRID:grid.42505.36) (ISNI:0000 0001 2156 6853); University of Southern California, Department of Aerospace and Mechanical Engineering, Viterbi School of Engineering, Los Angeles, USA (GRID:grid.42505.36) (ISNI:0000 0001 2156 6853); University of Southern California, Department of Biological Sciences, Dornsife College of Letters, Arts, and Sciences, Los Angeles, USA (GRID:grid.42505.36) (ISNI:0000 0001 2156 6853)